公开(公告)号：US12116618B2

公开(公告)日：2024-10-15

申请号：US17222772

申请日：2021-04-05

申请人： Caris Science, Inc.

发明人： Clive Gavin Brown ,  Koen Kas ,  Sven Agnes Jan Eyckerman

IPC分类号： C12Q1/6804 ,  C12N15/11 ,  C12N15/115 ,  G01N33/68

CPC分类号： C12Q1/6804 ,  C12N15/111 ,  C12N15/115 ,  G01N33/6818 ,  C12N2310/16 ,  C12N2320/11

摘要： The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.

公开(公告)号：US20240336925A1

公开(公告)日：2024-10-10

申请号：US18597673

申请日：2024-03-06

申请人： The Medical College of Wisconsin, Inc.

发明人： Daniel M. Lipinski ,  Chris A. Reid

IPC分类号： C12N15/115 ,  A61K48/00 ,  C12N15/67

CPC分类号： C12N15/115 ,  A61K48/005 ,  A61K48/0075 ,  C12N15/67 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2310/3519 ,  C12N2320/50 ,  C12N2750/14143 ,  C12N2830/00

摘要： The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.

公开(公告)号：US20240327847A1

公开(公告)日：2024-10-03

申请号：US18586102

申请日：2024-02-23

申请人： SANOFI

发明人： Jianping CUI ,  Tong-Ming FU ,  Allison Jessica MATTHEWS

IPC分类号： C12N15/115 ,  A61K48/00 ,  C12N15/10

CPC分类号： C12N15/115 ,  A61K48/0066 ,  C12N15/101 ,  C12N2310/16 ,  C12N2310/351 ,  C12N2830/50

摘要： The present disclosure provides methods and compositions for RNA affinity purification. In particular, the disclosure relates to compositions and methods of making and using mRNA comprising one or more aptamers which specifically bind an affinity ligand.

公开(公告)号：US12098370B2

公开(公告)日：2024-09-24

申请号：US17399934

申请日：2021-08-11

申请人： SomaLogic Operating Co., Inc.

发明人： Dominic Zichi ,  Sheri K Wilcox ,  Chris Bock ,  Daniel J. Schneider ,  Bruce Eaton ,  Larry Gold

IPC分类号： C12N15/115 ,  C12N9/74 ,  C12N15/10 ,  C12Q1/6811 ,  C12Q1/6816 ,  C12Q1/6832 ,  C12Q1/6834 ,  G01N33/53 ,  G01N33/58

CPC分类号： C12N15/115 ,  C12N9/6429 ,  C12N15/1048 ,  C12Q1/6811 ,  C12Q1/6816 ,  C12Q1/6832 ,  C12Q1/6834 ,  G01N33/5308 ,  G01N33/58 ,  C12N2310/16 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/333 ,  C12N2310/334 ,  C12N2310/335 ,  C12N2310/336 ,  C12N2330/31 ,  C12Q1/6811 ,  C12Q2525/205 ,  C12Q1/6816 ,  C12Q2565/514 ,  C12Q2525/205 ,  C12Q2525/161 ,  C12Q1/6832 ,  C12Q2537/101 ,  C12Q2525/205 ,  C12Q2523/313 ,  C12Q1/6834 ,  C12Q2525/205 ,  C12Q2525/161

摘要： The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.

公开(公告)号：US12097249B2

公开(公告)日：2024-09-24

申请号：US17581049

申请日：2022-01-21

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC分类号： A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/5748 ,  G01N33/6848 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2310/16 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N2570/00 ,  G01N2800/52

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240309379A1

公开(公告)日：2024-09-19

申请号：US18584707

申请日：2024-02-22

申请人： City of Hope

发明人： Hua Yu ,  Andreas Herrmann ,  Marcin Tomasz Kortylewski ,  Piotr Marek Swiderski

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61K47/54 ,  C12N15/11 ,  C12N15/115

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61K47/549 ,  C12N15/111 ,  C12N15/1138 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/13 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2310/3519 ,  C12N2320/30 ,  C12N2320/32

摘要： Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharamceutcial compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.

公开(公告)号：US12077760B2

公开(公告)日：2024-09-03

申请号：US17413550

申请日：2019-12-16

申请人： Board of Regents, The University of Texas System ,  Consiglio Nazionale delle Ricerche

发明人： Gabriel Lopez-Berestein ,  Paola Amero ,  Cristian Rodriguez-Aguayo ,  Rahul Mitra ,  Anil K. Sood ,  Vittorio De Franciscis ,  David Volk ,  Lokesh Ganesh L. Rao

IPC分类号： C12N15/115 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

CPC分类号： C12N15/115 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00 ,  C12N2310/16 ,  C12N2310/313 ,  C12N2310/322 ,  C12N2310/351 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/32

摘要： Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

公开(公告)号：US12060559B2

公开(公告)日：2024-08-13

申请号：US15734522

申请日：2019-06-19

申请人： CZ Biohub SF LLC ,  The Board of Trustees of the Leland Stanford Junior University

发明人： Jia Niu ,  Chelsea Lyons Gordon ,  Hyongsok Tom Soh

IPC分类号： C40B40/06 ,  C12N15/115 ,  C12Q1/6811 ,  C12Q1/686

CPC分类号： C12N15/115 ,  C12Q1/6811 ,  C12Q1/686 ,  C12N2310/16 ,  C12N2320/13

摘要： The disclosure is directed to methods and compositions for screening a library of aptamers for aptamers having a binding affinity to a target molecule. Specifically, non-natural nucleotides can be introduced onto aptamers immobilized on the surface of beads. The non-natural nucleotides can then be subsequently chemically modified to include additional binding agents. For example, copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions can be used to introduce a wide range of binding agents onto non-natural nucleotides on beads.

公开(公告)号：US20240263175A1

公开(公告)日：2024-08-08

申请号：US18010832

申请日：2021-06-16

申请人： Industry-University Cooperation Foundation Hanyang University Erica Campus

发明人： Hyung Shin YIM ,  Sol-Bi SHIN ,  Hay-Ran JANG

IPC分类号： C12N15/113 ,  A61P35/04

CPC分类号： C12N15/113 ,  A61P35/04 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2310/531

摘要： The present invention relates to a use of TSG6 shRNA as a therapeutic agent for metastatic solid cancer. More specifically, the present invention can be usefully used for treating cancer in which metastasis occurs by PLK1, which is known to be overexpressed, particularly in cancer, and the active form thereof or TGF-beta/Smad signaling by reducing proliferation, migration, and invasiveness of metastatic cancer cells through gene therapy that suppresses TSG6 mRNA expression.

公开(公告)号：US12054714B2

公开(公告)日：2024-08-06

申请号：US17114443

申请日：2020-12-07

申请人： Sirnaomics, Inc.

发明人： Xiaoyong Lu ,  Patrick Y. Lu ,  David M. Evans

IPC分类号： C07K7/08 ,  A61K47/64 ,  C07K7/06 ,  C12N15/113 ,  C12N15/117

CPC分类号： C12N15/113 ,  A61K47/64 ,  C07K7/08 ,  C12N15/117 ,  C07K7/06 ,  C12N2310/11 ,  C12N2310/127 ,  C12N2310/13 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2310/3513

摘要： Peptide docking vehicle compositions containing a therapeutic compound, such as an siRNA molecule, and a targeting ligand are provided, together with methods for their preparation and use. The compositions and methods allow targeted cell/tissue delivery of the therapeutic compound to a subject by linking a targeting ligand to the compound to provide enhanced therapeutic benefit. The subject may be an animal or a human.